IL105339A

Pharmaceutical compositions containing undenatured whey protein concentrate

Abstract

Undenatured whey protein concentrate is administered to HIV-seropositive individuals to elevate their blood mononuclear cells, glutathione (GSH) level, body weight and sense of well being. In addition T-helper cells concentration and their T-helper cells/T-suppressor cells ratio are slightly elevated.

Term

No projected expiry on record.

  1. Priority
  2. Filed
  3. Published
  4. Today

29 claims: 20 independent, 9 dependent

  1. 1
    A pharmaceutical composition for the treatment of HIV-seropositive individuals, cninprfcing a substantially undenatnred whey protein concentrate.
  2. 5
    The use of a substantially undenatured whey protein concentrate for the production of a medicament for the treatment of HIV-seropositive individuals in an amount sufficient to elevate blood mononuclear cell glutathione content, body weight and sense of well being, substantially as described in the specification.
  3. 6
    The use of a substantially undenatnred whey protein concentrate for the production of a medicament for the treatment of HIV-seropositive individuals in an amount, sufficient to elevate their T-helper cells concentration and their T-hclper cells/T-suppressor cells ratio, substantially as described in the specification.
  4. 7
    A pharmaceutical composition as in any one of claims 1 to 4, wherein the whey protein comprises a whey protein isolate mixture having two or more protein components of whey protein concentrate.
  5. 8
    A pharmaceutical composition as in any one of claims 1 to 4, wherein the whey protein concentrate comprises a substantially undenatured whey protein isolate mixture containing - bovine serum albumin, alpha-lactalbumin, lactoferrin proteins which are cystine rich, also being rich in glutamylcysteine, in an amount effective to increase blood mononuclear cell glutathione content, increase body weight and enhance the immune response.
  6. 9
    A pharmaceutical composition as in any one of claims 1 to 4, wherein the whey protein concentrate comprises a substantially undenatured whey protein isolate mixture containing whey proteins rich in glutamylcysteine and cystine, in an amount effective to increase blood mononuclear cell glutathione content, increase body weight and enhance the immune response.
  7. 10
    A pharmaceutical composition as in any one of claims 1 to 4, wherein the whey protein concentrate comprises a whey protein isolate mixture having selectively increased two or more whey proteins rich in glutamylcysteine and cystine, in an amount effective to increase blood mononuclear cell glutathione content, increase body weight and enhance the immune a response. .
  8. 11
    The use as in any one of claims 5 or 6, wherein the whey protein comprises a whey protein isolate mixture having two or more protein components of whey protein concentrate.
  9. 12
    The use as in any one of claims 5 or 6, wherein the whey protein concentrate comprises a substantially undenatured whey protein isolate mixture containing bovine serum albumin, alpha-lactalbumin, lactoferrin proteins which are cystine rich, also being rich in glutamylcysteine, in an amount effective to increase blood mononuclear cell glutathione content, increase body weight and enhance the immune respnse.
  10. 13
    The use as in any one of claims 5 or 6, wherein the whey protein concentrate comprises a substantially undenatured whey protein isolate mixture containing whey proteins rich in glutamylcysteine and cystine, in an amount effective to increase blood mononuclear cell glutathione content, increase body weight and enhance the immune response.
  11. 14
    The use as in any one of claims 5 or 6, wherein the whey protein concentrate comprises a whey protein isolate mixture having selectively increased two or more whey proteins rich in glutamylcysteine and cystine, in an amount effective to increase blood mononuclear cell glutathione content, increase body weight and enhance the immune response.
  12. 15
    A pharmaceutical composition as in any one of claims 1 to 4, 7, 8, 9 or 10, wherein the substantially undenatured whey protein concentrate has a bovine serum albumin level of at least 7% or more of the whey protein mixture.
  13. 17
    The use of any one of claims 5, 6, 11, 12, 13 or 14, wherein the substantially undenatured whey protein concentrate has a bovine serum albumin level of at least 7% or more of the whey protein mixture. «
  14. 19
    A pharmaceutical composition as in any one of claims 1 to 4, 7, 8,9, 10,15 or 16, wherein the substantially undenatured whey protein concentrate has a solubility index at pH 4.6 of .99% ־
  15. 20
    The use of any one of claims 5, 6, 11, 12, 13, 14, 17 or 18, wherein the substantially undenatured whey protein concentrate has a solubility index at pH 4.6 of 99%. b * - 105339/2
  16. 21
    A pharmaceutical composition as in any one of claims 1 to 4, 7, 8, 9, 10, 15, 16 or 19, wherein the amount of undenatured whey protein concentrate administered daily is in the range of about 8 to 40 g daily.
  17. 24
    The use as in any one of claims 5, 6, 11, 12, 13, 14, 17, 18 or 20, wherein the amount of substantially undenatured whey protein concentrate administered daily is in the range of about8־ to 40 g.
  18. 27
    A pharmaceutical composition as in any one of claims 1 to 4, 7, 8, 9, 10, 15 or 16, wherein the substantially undenatured whey protein concentrate has a solubility index at pH 4.6 of 98%.
  19. 28
    The use of any one of claims 5, 6, 11, 12, 13, 14, 17 or 18, wherein the substantially undenatured whey protein concentrate has a solubility index at pH 4.6 of 98%.
  20. 29
    A pharmaceutical composition as in any one of claims 1 to 4, 7, 8, 9, 10, 15, 16 or 27, wherein the substantially undenatured whey protein concentrate has a protein composition comprising beta-lactoglobulin 59.1 ± 4, alpha-lactalbumin22 ± 0.7, serum albumin 9.7 ± 1.0, immunoglobulin 9.0 ± 1.0.
Independent claims20